Small Molecule Drug Product Outsourcing
Source: ISR Reports
In Q4 2019, ISR asked 176 outsourcers of small molecule drug product manufacturing about the proportion of work allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work (40%) is allocated to preferred providers, even though 43% of respondents work at companies that do not have preferred provider agreements. To learn more, follow the link to the Small Molecule Drug Product CMO Quality Benchmarking report preview.
VIEW THE INFOGRAPHIC!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more